<DOC>
	<DOCNO>NCT00678288</DOCNO>
	<brief_summary>This study assess sorafenib second treatment patient previously receive sunitinib first-line treatment advance renal cell cancer , either respond progressed sunitinib intolerant sunitinib . This study ass combine usual dose sorafenib ( 200mg twice-daily ) low dose interferon ( 3 million international unit ( MIU ) five time week ) treat kidney cancer effectively current approve dose alone safe . In addition , patient respond treatment sorafenib alone combination interferon progressing , patient may receive sorafenib alone increase dose 300mg twice-daily , provided toxicity acceptable discretion investigator .</brief_summary>
	<brief_title>A Study Assess Sorafenib Alone Combination With Low-Dose Interferon Following Unsuccessful Treatment With Sunitinib Patients With Advanced Renal Cell Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Disease progression define Response Evaluation Criteria Solid Tumors ( RECIST ) criterion follow document stable disease well least 8 week sunitinib firstline treatment ( two cycle 4 week 2 week treatment ) And/or patient discontinue sunitinib treatment point due toxicity Study entry least 2 week treatment sunitinib maximum 8 week Memorial Sloane Kettering Cancer Centre ( MSKCC ) prognostic score low intermediate Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Patient must histologically confirm metastatic renal cell carcinoma predominant clear cell histology ( clear cell component 50 % ) . Patient exclude unresolved chronic toxicity grade &gt; 1 relate prior therapy sunitinib .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Renal Cell Cancer</keyword>
	<keyword>Interferon</keyword>
</DOC>